Market Overview

Research and Markets: Addiction - Pipeline Review: Latest updates and review of key players


Research and Markets ( has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering.

This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- A snapshot of the global therapeutic scenario for Addiction.

- A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Addiction pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Addiction.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Involved in Addiction Therapeutics Development

- Abbott Laboratories

- Aradigm Corporation

- Tekmira Pharmaceuticals Corp.

- Alkermes, Inc.

- Nanotherapeutics, Inc.

- Nabi Biopharmaceuticals

- Novartis AG

- EnVivo Pharmaceuticals

- Mitsubishi Tanabe Pharma Corporation

- Nippon Shinyaku Co., Ltd.

- Pfizer Inc.

- Sun Pharmaceutical Industries Limited

- Addex Pharmaceuticals

- AEterna Zentaris Inc.

- Catalyst Pharmaceutical Partners, Inc.

- Mundipharma International Limited

- Titan Pharmaceuticals, Inc.

- Biotie Therapies Corp.

- Orexo AB

- Mount Sinai School of Medicine

- Camurus AB

- Global Health Ventures Inc.

- Omeros Corporation

- ImmunoVaccine Technologies Inc.

- Targacept, Inc.

- Cary Pharmaceuticals Inc.

- CBio Limited

- Vanda Pharmaceuticals Inc.

- KYORIN Pharmaceutical Co., Ltd.

- Royalty Pharma

- Sihuan Pharmaceutical Holdings Group Ltd.

- Selecta Biosciences, Inc.

- Heptares Therapeutics Ltd.

- Envoy Therapeutics, Inc.

- Embera NeuroTherapeutics, Inc.

- Lightlake Therapeutics Inc.

- TheraQuest Biosciences, LLC

- Celtic Pharmaceutical Holdings L.P.

- Beech Tree Labs, Inc.

- Naurex, Inc.

- 22nd Century Limited, LLC

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

View Comments and Join the Discussion!

Partner Center